CERo Therapeutics (CERO) said on Monday that it presented preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models.
Shares surged 140% as intraday trading volume soared to more than 1.16 billion from a daily average of about 8.8 million.
RadNet (RDNT) shares soared as Q3 adjusted earnings and revenue reported late Sunday rose more than forecast.
Shares advanced 20% as intraday trading volume climbed to over 1.8 million from a daily average of about 523,000.
Jefferies was one of several brokerage firms to adjust its price target for Bristol-Myers Squibb (BMY). It raised the price target to $63 from $58 while maintaining the hold rating.
Shares of Bristol-Myers jumped 11%, with intraday trading volume at over 18.3 million compared with a daily average of about 10.6 million.
Price: 0.17, Change: +0.10, Percent Change: +140.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。